Joshua Richter, MD - Charting a New Course in Relapsed/Refractory Multiple Myeloma: The Emergence of BCMA-Targeted Therapies

episode

CME in Minutes: Education in Oncology & Hematology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

2026-09-23- KSR - Hour 2 51 min · 23 Sep 2026 · KSR

Kevin Harlan Is As Good As Anyone In Football | Hour 2 36 min · 23 Sep 2026 · The Dan Le Batard Show

12PM ET 09/23/2026 Newscast 3 min · 23 Sep 2026 · Fox News Hourly Update

2026-09-23- KSR - Hour 1 51 min · 23 Sep 2026 · KSR

A Dreamy Journey with a Dragon 56 min · 23 Sep 2026 · Get Sleepy: stories for sleep

American Idol Murder Trial: Wife’s Family Testifies, “We Loved Caleb So Much, We Didn’t Question Anything” 32 min · 23 Sep 2026 · Amy Robach & T.J. Holmes Present

Report any issue

Source

Recorded14 Oct 2022

Publisherc.answersincme.com ↗

Handlerec:766108

Show notes

Please visit answersincme.com/CHW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology/oncology discusses multiple myeloma. Upon completion of this activity, participants should be better able to: Recognize the unmet therapeutic needs with current treatments for patients with relapsed/refractory multiple myeloma (RRMM); Review the role of B-cell maturation antigen (BCMA) as a therapeutic target in multiple myeloma; and Outline clinical considerations for incorporating emerging BCMA-targeted bispecific antibodies into the treatment paradigm of RRMM, based on available evidence.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in